Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Pheochromocytoma 1Pain, Intractable 1Obesity 1Non-functioning Pituitary Adenoma 1Neoplasms 1Nausea 1Intrathecal Dexmedetomidine 1Dyspnea 1Delirium 1Death 1

Interventions

Vitamin D 2Tirzepatide 2Metformin 2licogliflozin 1indole-3-carbinol 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Tablets 1Specimen Handling 1Resistance Training 1Progestins 1Pregabalin 1Orlistat 1Organizational Objectives 1Omeprazole 1Observation 1Naltrexone 1Ketorolac 1Exergaming 1Exercise 1Exenatide 1Diet, Plant-Based 1Dexmedetomidine 1Dalteparin 1Counseling 1Cholecalciferol 1Calcium Citrate 1Calcium Carbonate 1Calcitriol 1CKD732 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Obesity × Dexmedetomidine × Clear all
NCT04730375 2022-05-05

Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients

National Cancer Institute, Egypt

Phase 2 Completed
70 enrolled
Other

Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡